EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 69: 1534-1543.
119. Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA; 92: 768–772.
120. Siemann DW, Rojiani AM (2002) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys; 53: 164–171. 121. Siemann DW, Horsman MR (2004) Targeting the tumor vasculature: A strategy to
improve radiation therapy. Expert Rev Anticancer Ther; 4: 321–327.
122. Siemann D, Shi W (2004) The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation. Eur J Cancer Suppl; 2: 49.
123. Stratford IJ (1992) Concepts and developments in radiosensitization of mammalian cells. Int J Radiat Oncol Biol Phys; 22: 529–532.
124. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E,
Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes
125. Takahashi Y, Bucana CD, Cleary KR, Ellis LM (1998) p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer; 79: 34–38.
126. Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev; 13: 139–168.
127. Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, Ikebe M, Kakeji Y (1995) Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer; 61: 732–737.
128. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D (1998) Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res; 18: 2567–2573.
129. Thor AD , Liu S , Moore DH , Edgerton SM (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer . J Clin Oncol; 17 : 470–477
130. Thomlinson R, Gray L (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer; 9: 539–549. 131. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res; 64: 3731–3736.
132. Tortora G, Melisi D, Ciardiello F (2004) Angiogenesis: A target for cancer therapy. Curr Pharm Des; 10: 11–26.
133. Toi M, Matsumoto T, Bando H (2001) Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol; 2:667–673. 134. Underiner TL, Ruggeri B, Gingrich DE (2004) Development of vascular
endothelial growth factor receptor (VEGFR) kinase inhibitors as antiangiogenic agents in cancer therapy. Curr Med Chem; 11: 731–745.
135. Unemori EN, Ferrara N, Bauer EA, Amento EP (1992) Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol; 153: 557–562.
136. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res; 49: 6449–6465.
137. Vaupel PW (1997) The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Paediatr; 209: 243–249.
138. Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res; 9: 1957–1971.
139. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey
SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 Inhibits Vascular Endothelial Growth Factor
Signaling, Angiogenesis, and Tumor Growth following Oral Administration. Cancer Res, 62, 4645–4655.
140. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung
DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the
VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med; 10: 145–147.
141. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ,
Wedge SR (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor
signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res; 10: 8587– 8593.
142. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L,
Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of
vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell; 6: 553–563.
143. Zachary I (2001). Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol; 280: C1375–C1386. 144. Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of
vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factorinduced endothelium migration and proliferation, respectively. J Biol Chem; 276: 32714–32719.
145. Zips D, Krause M, Hessel F, Westphal J, Brüchner K, Eicheler W, Dörfler A,
Grenman R, Petersen C, Haberey M, Baumann M (2003) Experimental study on
different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res; 23: 3869–3876.
146. Zips D, Eicheler W, Geyer P, Hessel F, Dörfler A, Thames HD, Haberey M,
Baumann M (2005) Enhanced susceptibility of irradiated tumor vessels to vascular
endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res; 65: 5374–5379.
147. Zirrolli JA, Bradshaw EL, Long ME, Gustafson DL (2005) Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. J Pharm Biomed Anal; 39: 705–711.